Lite Strategy, Inc. filings document the company’s public-company transition, operating results, Litecoin treasury strategy, and capital-allocation actions. Form 8-K disclosures include furnished financial results, the board-authorized common stock repurchase program, and equity securities activity tied to pre-funded warrants issued in a private placement.
The filings also cover governance and compensation matters, including annual meeting voting results, director elections and resignation, executive appointment to chief executive officer and the board, stock option grants, and approval of the 2026 Omnibus Equity Compensation Plan. SEC reports identify MEI Pharma, Inc. as the company’s former name and support the current Lite Strategy identity.
Lite Strategy, Inc. reported a fiscal 2026 net loss of $71.150 million, compared with $15.945 million in fiscal 2025, while pursuing a Litecoin treasury strategy and pre-clinical drug development. The $54.408 million change in fair value of digital assets included unrealized remeasurement losses and realized losses on collateral transfers and LTC sales. At June 30, 2026, cash and cash equivalents were $5.706 million and digital assets were $27.272 million; management believes those balances will fund operations for at least 12 months from issuance of the financial statements.
The company closed a $100.0 million PIPE on July 22, 2025, issuing 23,216,898 shares at $3.42 per share and pre-funded warrants for up to 6,022,869 shares at $3.4199 per warrant. Through June 30, 2026, it repurchased 4,378,525 shares at a weighted-average $1.12 per share, leaving approximately $20.2 million of its $25.0 million authorization available. The treasury strategy includes covered call options on some LTC holdings, with collateral potentially delivered if exercised. Voruciclib pre-clinical work in nononcologic indications began in fiscal 2026. The auditor's report highlighted risks related to Litecoin volatility and custody.
Alexander Schornstein reports that he no longer owns any common stock of Lite Strategy, Inc. He previously filed as a beneficial owner of the company’s common stock but has now reduced his holdings to zero.
On or about June 30, 2026, he liquidated all of his shares and, as of that date, ceased to be a beneficial owner. His beneficial ownership is listed as 0 shares, or 0.00% of the class, based on 34,025,200 shares of common stock issued and outstanding as referenced in a Form 10-Q dated May 13, 2026. He reports no sole or shared voting or dispositive power over any Lite Strategy, Inc. shares.
Lite Strategy, Inc. repurchased approximately 4.9 million shares of common stock between December 2025 and July 17, 2026 under its Share Repurchase Program, equal to 13% of the shares outstanding when the program began. The company deployed about $5.4 million at an average price of $1.11 per share, funded entirely through active treasury operations rather than borrowing.
The company sold a measured portion of its Litecoin (LTC) treasury asset and used covered call premiums to buy back stock when it traded at a substantial discount to the net asset value (NAV) of its Litecoin holdings. During the repurchase period, the discount to NAV reached the low 40% range and, according to the company, narrowed to below 25% as repurchases progressed. As of July 17, 2026, Lite Strategy holds 819,070 LTC against 31,882,648 shares outstanding and reports carrying no debt.
Preliminary, unaudited figures indicate fiscal year 2026 ended with cash of $5.7 million and total liabilities of $1.1 million, which the company notes may change once financial closing and the independent audit are complete. Lite Strategy plans to continue the repurchase program while it views it as value accretive and intends to fund additional buybacks through its active Litecoin treasury management.
Lite Strategy, Inc., a Nasdaq-listed company, presents itself as a public equity vehicle focused on Litecoin, aiming to institutionalize LTC as a strategic treasury asset. It emphasizes being the only Nasdaq-listed public company with Litecoin as its primary treasury reserve asset.
The company reports holding 830,378 LTC as of July 2, 2026, roughly 1.1% of total LTC supply, and running a covered call options program that has generated $0.7 million in premiums since October 2025. Capital allocation tools include a share repurchase program of up to $25 million designed to narrow the discount to NAV and a $1 million lead SAFE investment in LitVM at a $50 million post-money valuation cap, with a token warrant for up to 2% of LitVM’s token supply. Additional optionality comes from a pharmaceutical asset portfolio, including potential future payments of up to $62 million tied to ME-344 milestones.
Lite Strategy, Inc. director Flynn James P reported an open-market purchase of 25,000 shares of Common Stock. The shares were bought at a weighted-average price of $0.8555 per share in multiple trades, with prices ranging from $0.8363 to $0.88 per share. Following this transaction, he directly holds 125,000 Lite Strategy shares.
Lite Strategy, Inc. reported fiscal 2026 third quarter results, emphasizing its strategy of using Litecoin (LTC) as its primary treasury reserve asset and returning capital to shareholders. The company highlighted its active covered call options program, which has generated $0.7 million in net proceeds since October 2025.
Lite Strategy deployed covered call proceeds and 35,250 LTC to repurchase 1,629,136 shares under a broader $25 million share repurchase authorization, reflecting a focus on capital discipline and net asset value per share. Management also noted ongoing pre-clinical pharmaceutical programs as potential sources of non-dilutive capital.
The company framed recent Securities and Exchange Commission guidance indicating Litecoin exhibits digital commodity characteristics as a meaningful step toward regulatory clarity. Looking ahead, Lite Strategy plans to scale its options program, continue repurchases, and pursue strategic investments and partnerships that support broader Litecoin ecosystem growth.
Lite Strategy, Inc. reported a sharp increase in losses as it pivoted from drug development toward a Litecoin-focused treasury strategy for the quarter ended March 31, 2026. The company recorded a net loss of $23.7 million for the quarter and $58.1 million for the nine months, largely driven by a $46.0 million nine‑month loss from changes in the fair value of digital assets and related receivables.
Total assets rose to $57.8 million, dominated by $48.2 million of Litecoin-related digital assets and receivables, while cash and cash equivalents declined to $7.5 million. A $100.0 million PIPE financing in July 2025 funded the acquisition of LTC and new advisory and asset management warrants.
The company also authorized a $25.0 million share repurchase program and bought back about 1.6 million shares for $2.0 million during the nine months. Lite Strategy began writing covered call options on its LTC holdings to generate cash, exposing results to further digital asset price volatility under new fair value accounting.
Citadel-affiliated entities and Kenneth Griffin report beneficial ownership of Lite Strategy, Inc. common stock on an amended Schedule 13G. Griffin may be deemed to beneficially own 1,433,211 Shares, representing 3.9% of the outstanding common stock.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 1,085,626 Shares, or 3.0% of the class. Citadel Securities LLC, Citadel Securities Group LP and Citadel Securities GP LLC may each be deemed to beneficially own 347,585 Shares, or 0.9% of the class.
The ownership percentages are based on 36,769,677 Shares outstanding as of December 15, 2025. The reporting group certifies the securities were not acquired and are not held for the purpose of changing or influencing control of Lite Strategy.